New immunotherapy cocktail shows promise for tough lung cancer
NCT ID NCT05420220
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tested a combination of two drugs—KN046 (an immunotherapy) and axitinib (a targeted therapy)—in 95 people with advanced non-small cell lung cancer that had not been treated before. The goal was to see if the combo could shrink tumors and how safe it was. The trial is now complete, and results will help decide if further testing is warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KN046 (an experimental immunotherapy) combined with axitinib (a targeted cancer pill)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced lung cancer that has not responded to other therapies.
What could go wrong
This is an early-phase trial with only 95 participants, so results may not apply to everyone. Side effects from the drug combination could be serious, and the treatment may not work for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Linyi Cancer Hospital
Linyi, Shandong, China
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
-
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
-
The first affiliated hospital, Zhejiang university
Hangzhou, Zhejiang, China
-
Yantai Yuhuangding Hospital
Yantai, Shandong, China